Cargando…

Cost-Utility Analysis: Current Methodological Issues and Future Perspectives

The use of cost–effectiveness as final criterion in the reimbursement process for listing of new pharmaceuticals can be questioned from a scientific and policy point of view. There is a lack of consensus on main methodological issues and consequently we may question the appropriateness of the use of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nuijten, Mark J. C., Dubois, Dominique J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113167/
https://www.ncbi.nlm.nih.gov/pubmed/21713127
http://dx.doi.org/10.3389/fphar.2011.00029
_version_ 1782205894318096384
author Nuijten, Mark J. C.
Dubois, Dominique J.
author_facet Nuijten, Mark J. C.
Dubois, Dominique J.
author_sort Nuijten, Mark J. C.
collection PubMed
description The use of cost–effectiveness as final criterion in the reimbursement process for listing of new pharmaceuticals can be questioned from a scientific and policy point of view. There is a lack of consensus on main methodological issues and consequently we may question the appropriateness of the use of cost–effectiveness data in health care decision-making. Another concern is the appropriateness of the selection and use of an incremental cost–effectiveness threshold (Cost/QALY). In this review, we focus mainly on only some key methodological concerns relating to discounting, the utility concept, cost assessment, and modeling methodologies. Finally we will consider the relevance of some other important decision criteria, like social values and equity.
format Online
Article
Text
id pubmed-3113167
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-31131672011-06-27 Cost-Utility Analysis: Current Methodological Issues and Future Perspectives Nuijten, Mark J. C. Dubois, Dominique J. Front Pharmacol Pharmacology The use of cost–effectiveness as final criterion in the reimbursement process for listing of new pharmaceuticals can be questioned from a scientific and policy point of view. There is a lack of consensus on main methodological issues and consequently we may question the appropriateness of the use of cost–effectiveness data in health care decision-making. Another concern is the appropriateness of the selection and use of an incremental cost–effectiveness threshold (Cost/QALY). In this review, we focus mainly on only some key methodological concerns relating to discounting, the utility concept, cost assessment, and modeling methodologies. Finally we will consider the relevance of some other important decision criteria, like social values and equity. Frontiers Research Foundation 2011-06-08 /pmc/articles/PMC3113167/ /pubmed/21713127 http://dx.doi.org/10.3389/fphar.2011.00029 Text en Copyright © 2011 Nuijten and Dubois. http://www.frontiersin.org/licenseagreement This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with.
spellingShingle Pharmacology
Nuijten, Mark J. C.
Dubois, Dominique J.
Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
title Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
title_full Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
title_fullStr Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
title_full_unstemmed Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
title_short Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
title_sort cost-utility analysis: current methodological issues and future perspectives
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113167/
https://www.ncbi.nlm.nih.gov/pubmed/21713127
http://dx.doi.org/10.3389/fphar.2011.00029
work_keys_str_mv AT nuijtenmarkjc costutilityanalysiscurrentmethodologicalissuesandfutureperspectives
AT duboisdominiquej costutilityanalysiscurrentmethodologicalissuesandfutureperspectives